Insights
Featured Carousel
- Insights – September 2025
- The Informed Board – Summer 2025
- Insights: The Delaware Edition
- Latest Updates on the Trump Administration
- Trump Administration Regulatory Litigation Tracker
Topics Panel Section
Five States Enact ‘FARA-Lite’ Laws, With Implementation Underway
Several states have now adopted foreign-influence laws that require disclosure of lobbying and other advocacy activities conducted on behalf of certain foreign principals. Foreign companies — and even some U.S. subsidiaries and U.S. companies with foreign ownership — may be subject to onerous registration and reporting obligations under these laws.
Five States Enact ‘FARA-Lite’ Laws, With Implementation Underway
In a Landmark Decision, EU Court Clarifies When Pseudonymised Data Is Not Personal Data Under the GDPR
A recent ECJ decision clarifies that pseudonymised data is not automatically “personal data” under the GDPR, potentially reducing compliance burdens and expanding opportunities for data use in analytics, AI model training and service optimisation.
In a Landmark Decision, EU Court Clarifies When Pseudonymised Data Is Not Personal Data Under the GDPR
Several states have now adopted foreign-influence laws that require disclosure of lobbying and other advocacy activities conducted on behalf of certain foreign principals. Foreign companies — and even some U.S. subsidiaries and U.S. companies with foreign ownership — may be subject to onerous registration and reporting obligations under these laws.
Five States Enact ‘FARA-Lite’ Laws, With Implementation Underway
A recent ECJ decision clarifies that pseudonymised data is not automatically “personal data” under the GDPR, potentially reducing compliance burdens and expanding opportunities for data use in analytics, AI model training and service optimisation.
In a Landmark Decision, EU Court Clarifies When Pseudonymised Data Is Not Personal Data Under the GDPR
The FDA has updated its policy to reduce requirements for demonstrating biosimilarity. The changes should allow biosimilar companies to submit products to the agency sooner, potentially accelerating market entry and increasing biosimilar adoption.
FDA Policy Changes Could Bring Some Biosimilars to Market Faster
Recent state legislation and federal developments are requiring the removal of food additives, increased ingredient disclosures on labels and bans on ultraprocessed foods, creating a complex and evolving landscape for food industry M&A transactions.
Dealmaking in the Food Industry: Navigating State and Federal Food Regulations
FDA Policy Changes Could Bring Some Biosimilars to Market Faster
The FDA has updated its policy to reduce requirements for demonstrating biosimilarity. The changes should allow biosimilar companies to submit products to the agency sooner, potentially accelerating market entry and increasing biosimilar adoption.
FDA Policy Changes Could Bring Some Biosimilars to Market Faster
Dealmaking in the Food Industry: Navigating State and Federal Food Regulations
Recent state legislation and federal developments are requiring the removal of food additives, increased ingredient disclosures on labels and bans on ultraprocessed foods, creating a complex and evolving landscape for food industry M&A transactions.
Dealmaking in the Food Industry: Navigating State and Federal Food Regulations
Latest From Skadden
-
How the SEC May Overhaul Its Order Protection RuleNovember 7, 2025
-
Maryland Expected to Update Contribution Reporting Portal for Pay-to-Play Filers and Lobbyist Employers on November 10, Impacting December 1 FilingNovember 7, 2025
-
US and UK Issue Joint Cybersecurity Guidance for Operational Technology SystemsNovember 4, 2025